Pfizer (NYSE:PFE) Upgraded to “Strong-Buy” at StockNews.com

Pfizer (NYSE:PFEGet Rating) was upgraded by StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday.

PFE has been the subject of several other research reports. Citigroup raised their price objective on shares of Pfizer from $46.00 to $57.00 and gave the stock a “neutral” rating in a report on Tuesday, April 5th. Mizuho dropped their price objective on shares of Pfizer from $56.00 to $55.00 in a report on Thursday, February 10th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 price objective for the company. in a report on Tuesday, February 15th. The Goldman Sachs Group set a $54.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Tuesday, February 8th. Finally, Bank of America raised shares of Pfizer from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $59.00 to $70.00 in a report on Wednesday, January 5th. Eleven analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $58.00.

Shares of PFE opened at $51.84 on Tuesday. The stock has a market cap of $292.78 billion, a price-to-earnings ratio of 13.46, a P/E/G ratio of 0.77 and a beta of 0.77. The company has a quick ratio of 1.19, a current ratio of 1.40 and a debt-to-equity ratio of 0.47. Pfizer has a 12 month low of $37.96 and a 12 month high of $61.71. The company has a 50-day moving average price of $50.95 and a two-hundred day moving average price of $51.04.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.23. The firm had revenue of $23.84 billion during the quarter, compared to analysts’ expectations of $24.20 billion. Pfizer had a net margin of 26.97% and a return on equity of 34.53%. The company’s revenue for the quarter was up 104.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 earnings per share. Equities research analysts expect that Pfizer will post 7.28 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of The West boosted its position in shares of Pfizer by 4.5% during the third quarter. Bank of The West now owns 107,674 shares of the biopharmaceutical company’s stock worth $4,631,000 after purchasing an additional 4,634 shares in the last quarter. MJP Associates Inc. ADV lifted its position in Pfizer by 18.9% in the 4th quarter. MJP Associates Inc. ADV now owns 19,458 shares of the biopharmaceutical company’s stock valued at $1,102,000 after acquiring an additional 3,096 shares in the last quarter. Harrison & Co Wealth Management LLC bought a new stake in Pfizer in the 4th quarter valued at $1,455,000. Capital Advisors Inc. OK lifted its position in Pfizer by 3.9% in the 4th quarter. Capital Advisors Inc. OK now owns 541,381 shares of the biopharmaceutical company’s stock valued at $31,969,000 after acquiring an additional 20,514 shares in the last quarter. Finally, Avidian Wealth Solutions LLC lifted its position in Pfizer by 13.4% in the 3rd quarter. Avidian Wealth Solutions LLC now owns 39,122 shares of the biopharmaceutical company’s stock valued at $1,683,000 after acquiring an additional 4,616 shares in the last quarter. 64.96% of the stock is currently owned by institutional investors.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.